There's still plenty of time for growth investors to click the buy button on Tempus AI stock; however, it's critical to recognize the road ahead may be rocky. Therefore, only those comfortable with an ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

Ryan M. Bartolucci, the Chief Accounting Officer of Tempus AI , Inc. (NASDAQ:TEM), sold 6,059 shares of the company's Class A ...

We recently published a list of Top 10 AI Stocks Trending On Wall Street. In this article, we are going to take a look at ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

Analyst discusses AI stock Tempus AI, highlighting potential for profitability by 2025, insider selling, and sector risks.

Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.

Investing.com -- Tempus AI , Inc. (NASDAQ: TEM )周二盘前交易中股价上涨5%，此前该公司完成了对Ambry Genetics的收购。Ambry Genetics以其基因检测服务闻名，致力于研究基因与疾病之间的关系。此外，由于同为AI公司的Palantir收盘后发布强劲财报，也助推了Tempus AI的股价。Palantir盘前交易中上涨24%。

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics ...